EUVIMEDEUVIMED entdecken
EditorialLeitlinieOpen Access · CC BY-NC-ND 4.0

Should Methoxytyramine Routinely Be Included in the Guidelines for Biochemical Assessment of Pheochromocytomas and Paragangliomas?

Ann T Sweeney, Michael A Blake, Sina Jasim, Karel Pacak

AACE Clinical Case Reports · 2025-01 · 11 (1) · 3-4

DOI: 10.1016/j.aace.2024.11.005 ↗

Kurz gefasst

Editorial in der Zeitschrift AACE Clinical Case Reports, 2025-01. Verfasst von Ann T Sweeney und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, St Elizabeth's Medical Center, Brighton, Massachusetts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mustafa et al published an intriguing report on a “Dopamine-secreting carotid body paraganglioma (PGL) in a patient with an SDHB pathogenic variant.”1 In their discussion, they raise important clinical questions including whether dopamine-secreting PGLs are underdiagnosed due to a lack of adequate screening. Of note, the most recent Endocrine Society clinical guidelines, now outdated, do not recommend routine screening for dopamine or dopamine metabolites in patients with suspected pheochromocytoma or paragangliomas (PPGLs).

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Medicine, St Elizabeth's Medical Center, Brighton, Massachusetts.
  • Division of Abdominal Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
  • Division of Endocrinology, Metabolism, and Lipid Research, Washington University in St, Louis, School of Medicine St. Louis, Missouri.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Maryland.
  • AKESO, Prague, Czech Republic.

Zitieren

APA

Sweeney, A. T., Blake, M. A., Jasim, S., & Pacak, K. (2025). Should Methoxytyramine Routinely Be Included in the Guidelines for Biochemical Assessment of Pheochromocytomas and Paragangliomas?. AACE Clinical Case Reports, 11(1), 3-4. https://doi.org/10.1016/j.aace.2024.11.005

Vancouver

Sweeney AT, Blake MA, Jasim S, Pacak K. Should Methoxytyramine Routinely Be Included in the Guidelines for Biochemical Assessment of Pheochromocytomas and Paragangliomas?. AACE Clinical Case Reports. 2025;11(1):3-4. doi:10.1016/j.aace.2024.11.005

BibTeX
@article{Sweeney2025,
  author = {Sweeney, Ann T and Blake, Michael A and Jasim, Sina and Pacak, Karel},
  title = {Should Methoxytyramine Routinely Be Included in the Guidelines for Biochemical Assessment of Pheochromocytomas and Paragangliomas?},
  journal = {AACE Clinical Case Reports},
  year = {2025},
  volume = {11},
  number = {1},
  pages = {3--4},
  doi = {10.1016/j.aace.2024.11.005}
}
Kostenlos starten →